We are pulmonary hypertension professionals united in our vision for a world without pulmonary vascular disease. We believe we can achieve this together, and we won’t stop until we do.
PVRI 2026 registration & abstract portal open
Taking place 28 January – 1 February in Dublin, with the theme Celebrating 20 Years of Progress & Innovation to mark our 20th anniversary year, we invite you to join global leaders in PH for cutting-edge research, lively discussion, and impactful networking.
Our PHGPS has released initial findings from its adult cohort in a paper published in the ERJ Open Research. Initial findings have also identified 10 global calls to action for improving PH care, which aim to enhance equitable access to care and research opportunities, particularly across areas of geographical disparities.
The next series of the free PVRI Digital Webinar Series will kick off 11 September 2025. The new series will alternate between 'Cutting Edge Innovation in Clinical & Experimental PH' and 'Living Legends in PH: History & Personal Perspectives' sessions.
This November, we’re coming together as one global team to shine a light on PH research and innovation during PH Awareness month through our new fundraising challenge: Breath Beyond Borders. PVRI friends across the world are taking on a personal challenge that pushes their limits, and we invite you to participate.
Whether you’re a pulmonary hypertension specialist, a pharmaceutical or industry colleague, a regulator, a patient, or a caregiver, joining our growing global family means you share our vision to reduce the global burden of pulmonary vascular disease.
Registration and abstract submissions are now open for PVRI 2026, taking place 28 January – 1 February in Dublin. With the theme ‘Celebrating 20 Years of Progress & Innovation’, join global leaders in pulmonary vascular science for cutting-edge research, lively discussion, and impactful networking.
Join an esteemed panel of international leaders as they share their approaches to bridging pediatric patients to lung transplantation. This dynamic session will feature focused presentations from each speaker, followed by interactive panel discussions of two real-world clinical cases.
'Pulmonary Hypertension in the Shadow of Infections: Challenges in Indian Practice' is part of the Virtual Symposium Series by the iPVD, a global education programme that highlights top-notch research on inflammation and infectious PVD.
Part of the 'Hypoxia in pulmonary vascular research – altitude and beyond' webinar series by the High Altitude Task Force, who raise awareness and understanding of PH linked to high altitude and organise scientific conferences in regions affected by high altitudes.
Evidence on the predictive ability of risk assessment models for event-free survival (EFS) in patients with pulmonary arterial hypertension is scarce. We aimed to investigate the relationship between risk status at 6 months after diagnosis (6 M) and EFS, by three risk models: Multicomponent Improvement (MCI), ESC/ERS 4-Strata Risk (4SR), and noninvasive French PH Registry Score (FRS). Data collected in the Swedish PAH Registry 2008–2021 were used.
Pulmonary arterial hypertension (PAH) is a progressive vascular disease characterized by small artery occlusion, increased pulmonary vascular resistance, and right heart failure. HSPH1, a member of the heat shock protein family, has been shown to inhibit protein aggregation but its role in PAH remains unclear. The purpose of this study was to explore the expression pattern and potential mechanism of HSPH1 in PAH, and to provide new diagnostic markers for PAH.
The objective of this study is to assess the effect of subcutaneous treprostinil (TRE) administered peri-operatively after Fontan operation on chest tube duration (CTD), hospital length of stay (LOS), and post-operative hemodynamics. This is a single center randomized, blinded, placebo-controlled study of pediatric patients with single ventricle congenital heart disease undergoing Fontan operation between September 2015 and September 2019.
Our Pulmonary Hypertension Global Patient Survey (PHGPS), the largest survey to date to explore the perspectives of patients with PH at a global scale, has released initial findings from its adult cohort of 3,329 patients living with PH.
We’re excited to announce the relaunch of the PVRI Digital Webinar Series, beginning September 2025. This free monthly series, open to all, brings together the global PH community for keynote presentations, rich discussion, and the opportunity to learn cutting-edge new research.
This PH Awareness Month, we’re inviting you to join the global PVRI community for our very first Breath Beyond Borders challenge. Throughout November, PVRI members and friends around the world will be taking on personal challenges — walking, running, cycling, speed skating, or even playing the piano — to shine a light on PH research and innovation, and raise funds for PVRI along the way.
We’re thrilled to announce a new chapter in the leadership of PVRI’s Innovative Drug Discovery Initiative (IDDI). We warmly welcome industry reps, Gil Golden (UTC) and Sidra Hoffman (Gossamer Bio), to the IDDI Leadership Team. They’ll be joining Sandeep Sahay and Luke Howard, who remain on as IDDI Leaders.
